StockData
Immunocore Holdings plc logo

Immunocore Holdings plc (IMCR) stock

IMCRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 7/3015% below fair value
$26.63−0.88 (-3.20%)

Close on Nov 19, 2026Market cap $1.37BP/E –Yield 0.00%

Immunocore net income

Net income is the profit left for shareholders after every expense, interest and tax.

Immunocore's net income for the twelve months ending Jun 30, 2026 was -$18.07M. For fiscal 2025 it was -$35.51M. The highest annual figure on record is -$35.51M in fiscal 2025.

Annual net income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$35.51M–
FY2024Dec 31, 2024-$51.09M–
FY2023Dec 31, 2023-$55.29M–
FY2022Dec 31, 2022-$52.54M–
FY2021Dec 31, 2021-$180.03M–

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$808.00K–
Q1 FY2026Mar 31, 2026$12.97M+158.2%
Q4 FY2025Dec 31, 2025-$30.06M–
Q3 FY2025Sep 30, 2025-$177.00K-102.0%
Q2 FY2025Jun 30, 2025-$10.30M–
Q1 FY2025Mar 31, 2025$5.02M–
Q4 FY2024Dec 31, 2024-$23.77M–
Q3 FY2024Sep 30, 2024$8.74M+864.2%
Q2 FY2024Jun 30, 2024-$11.62M–
Q1 FY2024Mar 31, 2024-$24.44M–
Q4 FY2023Dec 31, 2023-$19.73M–
Q3 FY2023Sep 30, 2023$906.00K–
Q2 FY2023Jun 30, 2023-$17.01M–
Q1 FY2023Mar 31, 2023-$19.45M–

More Immunocore figures

See a number that looks wrong?